Analysts expect athenahealth, Inc. (NASDAQ:ATHN) to post $323.37 million in sales for the current quarter, Zacks Investment Research reports. Twenty analysts have made estimates for athenahealth’s earnings. The lowest sales estimate is $313.50 million and the highest is $337.30 million. athenahealth posted sales of $288.20 million during the same quarter last year, which would indicate a positive year over year growth rate of 12.2%. The business is expected to announce its next earnings results on Thursday, February 1st.
On average, analysts expect that athenahealth will report full-year sales of $323.37 million for the current fiscal year, with estimates ranging from $1.20 billion to $1.24 billion. For the next year, analysts expect that the firm will post sales of $1.36 billion per share, with estimates ranging from $1.31 billion to $1.42 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow athenahealth.
athenahealth (NASDAQ:ATHN) last announced its quarterly earnings results on Thursday, October 19th. The health services provider reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.06. The company had revenue of $304.60 million during the quarter, compared to analysts’ expectations of $310.52 million. athenahealth had a return on equity of 6.78% and a net margin of 2.65%. athenahealth’s quarterly revenue was up 10.1% on a year-over-year basis. During the same period last year, the business earned $0.60 earnings per share.
A number of analysts have weighed in on the company. Piper Jaffray Companies reaffirmed a “buy” rating and set a $167.00 price objective on shares of athenahealth in a research report on Tuesday, October 17th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $170.00 price objective (up from $150.00) on shares of athenahealth in a research report on Wednesday, August 2nd. Robert W. Baird reaffirmed a “buy” rating and set a $170.00 price objective on shares of athenahealth in a research report on Thursday, August 31st. KeyCorp reaffirmed a “buy” rating and set a $170.00 price objective on shares of athenahealth in a research report on Sunday, September 17th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $184.00 price objective on shares of athenahealth in a research report on Friday, October 20th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $143.22.
Shares of athenahealth (ATHN) opened at $129.44 on Monday. The company has a market capitalization of $5,179.93, a P/E ratio of 109.69, a PEG ratio of 5.01 and a beta of 1.57. athenahealth has a 12-month low of $90.11 and a 12-month high of $158.66. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.67 and a quick ratio of 1.67.
In related news, CEO Jonathan Bush sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $124.17, for a total value of $496,680.00. Following the completion of the transaction, the chief executive officer now directly owns 319,807 shares of the company’s stock, valued at approximately $39,710,435.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jonathan D. Porter sold 300 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $130.38, for a total value of $39,114.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,283 shares of company stock valued at $1,741,372. Company insiders own 3.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its holdings in shares of athenahealth by 37.3% in the first quarter. Dimensional Fund Advisors LP now owns 121,650 shares of the health services provider’s stock valued at $13,708,000 after buying an additional 33,061 shares in the last quarter. Aperio Group LLC grew its position in athenahealth by 10.6% during the second quarter. Aperio Group LLC now owns 6,709 shares of the health services provider’s stock valued at $943,000 after buying an additional 641 shares during the period. Kornitzer Capital Management Inc. KS grew its position in athenahealth by 19.4% during the second quarter. Kornitzer Capital Management Inc. KS now owns 205,250 shares of the health services provider’s stock valued at $28,848,000 after buying an additional 33,390 shares during the period. Tokio Marine Asset Management Co. Ltd. bought a new position in athenahealth during the second quarter valued at about $1,153,000. Finally, Bessemer Group Inc. grew its position in athenahealth by 13.7% during the second quarter. Bessemer Group Inc. now owns 938 shares of the health services provider’s stock valued at $132,000 after buying an additional 113 shares during the period.
athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for athenahealth Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth Inc. and related companies with MarketBeat.com's FREE daily email newsletter.